Torsemide

• CAT Number: A000211
• CAS Number: 56211-40-6
• Molecular Formula: C16H20N4O3S
• Molecular Weight: 348.4
• Purity: ≥95%
• Synonyms: TORSEMIDE; 56211-40-6; Demadex; Torasemida; Torasemidum
• Target: Cl- channel
• Storage: -20°C
• InChI: 1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)
• InChIKey: NGBFQHCMQULJNZ-UHFFFAOYSA-N
• SMILES: CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C

Torasemide is a pyridine-sulfonyl urea type loop diuretic mainly used in the management of edema associated with congestive heart failure. It is also used at low doses for the management of hypertension.

Reference

1: Greene SJ, Mentz RJ. Potential advantages of torsemide in patients with heart
failure: more than just a /’water pill/’? Eur J Heart Fail. 2017 Oct 29. doi:
10.1002/ejhf.1024. [Epub ahead of print] PubMed PMID: 29082584.

2: Shah S, Pitt B, Brater DC, Feig PU, Shen W, Khwaja FS, Wilcox CS. Sodium and
Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short
Duration of Diuretic Action. J Am Heart Assoc. 2017 Oct 5;6(10). pii: e006135.
doi: 10.1161/JAHA.117.006135. PubMed PMID: 28982672.

3: Adin D, Johnson PR, Kim CH, Nguyenba T, Rosen S. Long-term Stability of a
Compounded Suspension of Torsemide (5 mg/mL) for Oral Administration. J Vet
Intern Med. 2017 Sep 15. doi: 10.1111/jvim.14819. [Epub ahead of print] PubMed
PMID: 28913839.

4: Lai S, Momper JD, Yam FK. Evaluation of the effect of torsemide on warfarin
dosage requirements. Int J Clin Pharm. 2017 Aug;39(4):831-835. doi:
10.1007/s11096-017-0479-6. Epub 2017 May 18. PubMed PMID: 28523460.

5: El-Shenawy AA, Ahmed MM, Mansour HF, Abd El Rasoul S. Torsemide Fast
Dissolving Tablets: Development, Optimization Using Box-Bhenken Design and
Response Surface Methodology, In Vitro Characterization, and Pharmacokinetic
Assessment. AAPS PharmSciTech. 2017 Aug;18(6):2168-2179. doi:
10.1208/s12249-016-0697-6. Epub 2017 Jan 3. PubMed PMID: 28050711.

6: Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz
JA, Tang WH, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, O/’Connor CM.
Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the
ASCEND-HF Trial). Am J Cardiol. 2016 Feb 1;117(3):404-11. doi:
10.1016/j.amjcard.2015.10.059. Epub 2015 Nov 18. PubMed PMID: 26704029; PubMed
Central PMCID: PMC4718787.

7: Sadek SA, Rashed LA, Bassam AM, Said ES. Effect of aliskiren, telmisartan and
torsemide on cardiac dysfunction in l-nitro arginine methyl ester (l-NAME)
induced hypertension in rats. J Adv Res. 2015 Nov;6(6):967-74. doi:
10.1016/j.jare.2014.11.003. Epub 2014 Nov 20. PubMed PMID: 26644935; PubMed
Central PMCID: PMC4642170.

8: Mentz RJ, Velazquez EJ, Metra M, McKendry C, Chiswell K, Fiuzat M, Givertz MM,
Voors AA, Teerlink JR, O/’Connor CM. Comparative effectiveness of torsemide versus
furosemide in heart failure patients: insights from the PROTECT trial. Future
Cardiol. 2015 Sep;11(5):585-95. doi: 10.2217/fca.15.56. Epub 2015 Sep 25. PubMed
PMID: 26403536; PubMed Central PMCID: PMC5558519.

9: Matthaei J, Brockmöller J, Tzvetkov MV, Sehrt D, Sachse-Seeboth C, Hjelmborg
JB, Möller S, Halekoh U, Hofmann U, Schwab M, Kerb R. Heritability of metoprolol
and torsemide pharmacokinetics. Clin Pharmacol Ther. 2015 Dec;98(6):611-21. doi:
10.1002/cpt.258. Epub 2015 Oct 19. PubMed PMID: 26344676.

10: Mentz RJ, Buggey J, Fiuzat M, Ersbøll MK, Schulte PJ, DeVore AD, Eisenstein
EL, Anstrom KJ, OʼConnor CM, Velazquez EJ. Torsemide versus furosemide in heart
failure patients: insights from Duke University Hospital. J Cardiovasc Pharmacol.
2015 May;65(5):438-43. doi: 10.1097/FJC.0000000000000212. PubMed PMID: 25945862;
PubMed Central PMCID: PMC4423558.